Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Synovitis, Pigmented Villonodular 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Melanoma 1Hodgkin Disease 1Hemangiosarcoma 1Glioblastoma 1Giant Cell Tumor of Tendon Sheath 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × pexidartinib × Clear all
NCT01217229 2020-06-30

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Daiichi Sankyo

Phase 2 Completed
20 enrolled 7 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡